Chest
Volume 126, Issue 4, Supplement, October 2004, Page 807S
Poster PresentationsEfficacy of Advair Diskus 250/50 (Fluticasone Propionate/Salmeterol) or Ipratropium/Albuterol in Patients with COPD Associated with Chronic Bronchitis and/or Emphysema
Section snippets
Abstract
PURPOSE: Advair 250/50 via Diskus in COPD has been studied primarily in patients with COPD associated with chronic bronchitis (CB). This post hoc analysis evaluated treatment effects in patients with CB + emphysema or emphysema alone.
METHODS: Two multicenter, randomized, double-blind studies comparing the efficacy and safety of Advair 250/50 BID with ipratropium/albuterol 36/206 mcg QID (IB/ALB) over 8 weeks. Patients were identified by study investigators as having COPD associated with CB,
References (0)
Cited by (81)
Asthma and COPD: distinct diseases or components of a continuum?
2023, Asthma in the 21st Century: New Research AdvancesThe Physiology of Asthma-Chronic Obstructive Pulmonary Disease Overlap
2022, Immunology and Allergy Clinics of North AmericaEarly lung development: Lifelong effect on respiratory health and disease
2013, The Lancet Respiratory MedicinePrevalence and clinical features of most frequent phenotypes in the Italian COPD population: The CLIMA study
2021, Multidisciplinary Respiratory MedicineDistinctive patterns of pulmonary function change according to baseline lung volume and diffusing capacity
2020, International Journal of Tuberculosis and Lung DiseaseSmall airway remodeling in a sheep model of bleomycin-induced pulmonary fibrosis
2020, Experimental Lung Research
Copyright © 2004 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.